Non-muscle Invasive Bladder Cancer — CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
Citation(s)
A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer (VLA-012 CANON)